In an exclusive interview at SABCS 2019, Dawn Hershman, MD, MS, professor of medicine and epidemiology at Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, discusses how the cost of breast cancer treatment is directly associated with rates of adherence, and explains…

“From a payer's perspective, this is a mechanism to address the dramatically rising cost of cancer care in a way that not only reduces costs, but also improves quality at the same time,” explained Charles Saunders, MD, chief executive office, Integra Connect.

Ashley Chiara, PharmD, clinical pharmacy consultant, Clinical Pharmacy Services, University of Massachusetts Medical School, explains why it is important to open up access to mental health services, destigmatize the discussion about patients who have mental health disorders and need treatment, and…

Jason Rose, CEO of AdhereHealth, a health care technology solutions company, explains what steps health plans can take to enhance their star ratings and boost adherence, as well as addresses the role social determinants play in improving patient outcomes.

Caraline Coats, vice president of population health strategy, and Andrew Renda, MD, associate vice president of population health, both from Humana, discuss their company’s Bold Goal initiative, the importance of addressing social determinants of health, and offer their insight regarding the future…

During this discussion, we talked to Lynn Barr, CEO and founder of Caravan Health, and she shared insights into the Medicare Shared Savings “Pathways to Success" Program.

Jordan Bazinsky, executive vice president and administrative officer for Cotiviti, breaks down various factors impacting innovation, including market trends that he believes are both headwinds and tailwinds to innovation, as well as shares a framework based on what’s happening in the current health…

Steven Feldman, MD, PhD, professor of dermatology at the Wake Forest School of Medicine, discusses costs associated with psoriasis drugs and focuses specifically on the impact these costs have on insurers.

Nan Li, health outcomes researcher at Janssen, discusses the importance of understanding health care utilization, expenditures, and work productivity among patients with RA with or without comorbidities.

In this podcast, Parag Joshi, MD, discusses the 2018 cholesterol guidelines and how these cholesterol-lowering drugs can be used in practice. He also discusses the cost-effectiveness of PCSK9 inhibitors.